TOS-358 is the first highly specific, potent inhibitor of PI3Kα EMERYVILLE, Calif. , April 13, 2023 /PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending ...

TOS-358 highlights the company's ability to identify highly specific and potent molecules against previously poorly drugged or undrugged targets. About Totus Medicines ...

Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent inhibitor of phosphoinositide 3-kinase α (PI3Kα), TOS-358, which is being developed for the ...

TOS-358 is a highly selective covalent inhibitor of PI3Kα. TOS-358 demonstrates clear superiority compared to non-covalent molecules by achieving deep and durable inhibition of PI3K-AKT signaling ...

The poster exhibits data from the clinical development candidate TOS-358, the first highly selective covalent molecule targeting PI3Kα, which is the most mutated oncogene in cancer.